South Africa Oncology Therapeutics Market Report 2022 to 2030

South Africa Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the South Africa Oncology Therapeutics Market will reach a value of $2.5 Bn from $1.2 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Oncology Therapeutics Market in South Africa is dominated by a few domestic pharmaceutical companies such as Aspen Pharmacare, Adcock Ingram, and Roche South Africa. The Oncology Therapeutics Market in South Africa is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for South Africa Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10ZAPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Dr. Vishwa Modhia

Buy Now

South Africa Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the South Africa Oncology Therapeutics Market will reach a value of $2.5 Bn from $1.2 Bn in 2022, growing at a CAGR of 9.6% during 2022-30.

South Africa is an upper-middle-income, developing country located at the southern tip of the African continent. South Africa's healthcare system is organised into public (83%) and private (17%) sectors. South Africa is divided into nine provinces, and the prevalence and treatment options for lung cancer differ by location. In 1986, the National Cancer Registry was established to provide statistics on cancer incidence in South Africa. It is a pathology-based system that was last updated in 2014. In South Africa, the top three malignancies affecting males are prostate, colorectal, and lung, whereas the top three cancers affecting women are breast, cervical, and colorectal.

Cancer is becoming more common in South Africa and around the world. However, the worldwide death rate is decreasing. When the figures are corrected for population growth and age, the age-standardized death rate declined by 15% between 1990 and 2019. South Africa's government spent 4.6% of its GDP on healthcare in 2020.

South Africa Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The South African National Department of Health (NDoH) produced the National Cancer Strategic Framework (NCSF): 2017-2022, which describes the country's plan for attaining equal access to cancer services for the South African population. Cancer, as an NCD, contributes to South Africa's quadruple disease burden. Non-profit organisations like the Cancer Association of South Africa contribute to cancer research by educating the public about symptoms, early detection, screening, and risk reduction. South Africa has various cancer research institutions, including the South African Oncology Consortium and the Cancer Association of South Africa. These aspects could boost South African Oncology Therapeutics Market.

Market restraints

The National Strategic Cancer Framework (2017-2022), which had big plans to improve cancer prevalence rates, has not lived up to expectations. The government's prevention, screening, and treatment measures have been limited due to a range of problems (including the cost of infrastructure, insufficient access to medication, and weak health referral pathways). There are fewer than 40 medical oncologists in South Africa. The majority of them are located in Gauteng Province. New therapies must go through a lengthy registration process, which in some cases can take up to 5 years. New agents are occasionally made available through compassionate use programmes. There are around 83 teletherapy units in the country. Only three of the country's nine provinces contain more than 64 of these (77 per cent). Cancer is also a prominent cause of death in the country, accounting for 10% of all deaths. These factors may deter new entrants into the South Africa Oncology Therapeutics Market.

Competitive Landscape

Key Players

Aspen Pharmacare: Aspen Pharmacare is a South African pharmaceutical company that specializes in a wide range of therapeutic areas, including oncology. The company offers a variety of oncology products, including chemotherapy drugs, supportive care drugs, and targeted therapy drugs
Adcock Ingram: Adcock Ingram is another major player in South Africa's oncology therapeutics market. The company offers a range of oncology products, including chemotherapy drugs, supportive care drugs, and targeted therapy drugs
Cipla Medpro: Cipla Medpro is a subsidiary of the Indian pharmaceutical company Cipla Limited. The company has a strong presence in South Africa's oncology market, offering a variety of oncology products, including chemotherapy drugs, supportive care drugs, and targeted therapy drugs
Roche South Africa: Roche South Africa is the local subsidiary of the Swiss pharmaceutical company Roche. The company has a strong presence in South Africa's oncology market, offering a range of oncology products, including chemotherapy drugs, targeted therapy drugs, and supportive care drugs
Pfizer South Africa: Pfizer South Africa is the local subsidiary of the American pharmaceutical company Pfizer. The company offers a variety of oncology products, including chemotherapy drugs, targeted therapy drugs, and supportive care drugs

Healthcare Policies and Reimbursement Scenarios

The South African Health Items Regulatory Authority (SAHPRA) is responsible for the approval and regulation of therapeutic products, especially cancer therapies, in South Africa. SAHPRA took over the functions of the Medicines Control Council (MCC) and the Directorate of Radiation Control (DRC), both of which were situated under the National Department of Health (NDoH). The South African government provides reimbursement for cancer treatment costs through the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the South Africa Oncology Therapeutics market will reach a value of $2.5 Bn from $1.2 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030.

The South African Health Items Regulatory Authority (SAHPRA) is responsible for the approval and regulation of therapeutic products, especially cancer therapies, in South Africa.

The Oncology Therapeutics Market in South Africa is dominated by a few domestic pharmaceutical companies such as Aspen Pharmacare, Adcock Ingram, and Roche South Africa.